The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is
now challenging the entire lupus community, from geneticists to clinical investigators …

Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the loss of
self-tolerance and formation of nuclear autoantigens and immune complexes resulting in …

Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …

Objective To assess the efficacy and safety of the type I interferon receptor antibody,
anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This …

Systemic lupus erythematosus (SLE) is a worldwide chronic autoimmune disease which
may affect every organ and tissue. Genetic predisposition, environmental triggers, and the …

The vast interindividual clinical variability observed in any microbial infection—ranging from
silent infection to lethal disease—is increasingly being explained by human genetic and …

Type I and type II interferons (IFN) are central to both combating virus infection and
modulating the antiviral immune response. Indeed, an absence of either the receptor for type …

Multiple type I interferons and interferon-γ (IFN-γ) are expressed under physiological
conditions and are increased by stress and infections, and in autoinflammatory and …

Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …

The treat-to-target (T2T) concept has improved outcomes for patients with diabetes,
hypertension and rheumatoid arthritis. This therapeutic strategy involves choosing a well …